Sutro Biopharma Stock Price, News & Analysis

Sutro Biopharma (NASDAQ: STRO) announced the dosing of the first patient in the Phase 1 dose-expansion study of STRO-002, a folate receptor alpha-targeting antibody-drug conjugate aimed at treating ovarian cancer. The study will assess STRO-002's efficacy and safety at dosages of 4.3 and 5.2 mg/kg every three weeks. Preliminary results indicated improved patient outcomes in a heavily pre-treated population. Sutro plans to expand this study across 35 clinical sites in the U.S. and Europe, and a cohort for endometrial cancer is anticipated later this year.

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast will be available on the company's website, with a replay for 30 days post-event. Sutro, based in South San Francisco, specializes in drug discovery and manufacturing, focusing on cancer and autoimmune therapeutics through its innovative protein engineering platforms. Key product candidates include STRO-001 and STRO-002, both undergoing Phase 1 trials for various cancers.

Sutro Biopharma (Nasdaq: STRO) has completed an upsized public offering of 6,900,000 shares of common stock priced at $21.00 per share, resulting in gross proceeds of $144.9 million. This offering, which included the full exercise of underwriters' options, will fund the clinical development of STRO-001 and STRO-002, alongside enhancing its technology platform for new product candidates. Proceeds will also cover general corporate purposes. The offering was managed by Cowen, Piper Sandler, and Wells Fargo Securities.

Sutro Biopharma (Nasdaq: STRO) announced a public offering of 6,000,000 shares at $21.00 per share, raising gross proceeds of $126 million before expenses. The offering is expected to close by December 11, 2020. Sutro plans to utilize the net proceeds for the continued clinical development of STRO-001 and STRO-002, expand its technology platform, enhance its product pipeline, and manage general corporate purposes. The underwriters received a 30-day option for an additional 900,000 shares.

Sutro Biopharma (Nasdaq: STRO) announced a proposed underwritten public offering of 5,000,000 shares of common stock, with an additional 750,000 shares available for purchase by underwriters. The funds will primarily support the clinical development of STRO-001 and STRO-002, along with advancing its technology platform. The offering is contingent on market conditions and the timing remains uncertain. Cowen, Piper Sandler, and Wells Fargo Securities are the lead managers of the offering, which is being conducted under an SEC registration statement.

Sutro Biopharma (NASDAQ: STRO) announced its Phase 1 dose-escalation trial results for STRO-001, an antibody-drug conjugate targeting CD74 in Non-Hodgkin Lymphoma (NHL), during the virtual ASH Annual Meeting. With 21 NHL patients treated, preliminary data show:

• 90% treatment-emergent adverse events were grade 1 or 2.
• 1 complete response and 2 partial responses in patients with diffuse large B-cell lymphoma.
• Stable disease observed in certain patients with follicular and marginal zone lymphoma.

The study continues to explore the 3.5 mg/kg dose level.

Sutro Biopharma (NASDAQ: STRO) provided a clinical update on STRO-002, an antibody-drug conjugate targeting ovarian cancer. The Phase 1 trial achieved enrollment of 39 patients, with significant results: 10 out of 31 evaluable patients meeting RECIST response criteria, including 1 complete response. Disease control was observed in 74% at 12 weeks and 58% at 16 weeks. The treatment was well-tolerated, with most adverse events being mild. Next steps include randomizing dose levels for expanded patient treatment starting January 2021 and evaluating broader patient populations.

Sutro Biopharma (NASDAQ: STRO) announced the appointment of Jon M. Wigginton, M.D. to its Board of Directors on December 1, 2020. Dr. Wigginton brings over 25 years of experience in clinical oncology and drug development, with previous leadership roles at Bristol Myers Squibb and MacroGenics. His expertise in immuno-oncology is expected to enhance Sutro's clinical pipeline of antibody drug-conjugates, including STRO-001 and STRO-002. The addition of Dr. Wigginton comes at a critical time as Sutro advances its proprietary technology and aims to expand its therapeutic reach.

Sutro Biopharma (NASDAQ: STRO) will host a live webcast on Dec. 3, 2020, at 5pm ET to update on the Phase 1 study of STRO-002, a targeted ADC for ovarian cancer. This follows the data cut-off of Oct. 30, 2020. Principal Investigators, Dr. Lainie P. Martin and Dr. Wendel Naumann, will present findings from the study. The trial is registered under NCT03748186 and aims to evaluate the safety and effectiveness of STRO-002. The webcast registration link is available on Sutro's website.